Other

Debt and Equity Securities, Unrealized Loss

Vertex Pharmaceuticals Debt and Equity Securities, Unrealized Loss increased by 97.8% to $17.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 56.2%, from $40.60M to $17.80M. Over 5 years (FY 2020 to FY 2025), Debt and Equity Securities, Unrealized Loss shows an upward trend with a 157.8% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ2 2018
Last reportedQ1 2026
Metric ID: other_debtand_equity_securities_unrealized_loss

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$47.00K$990.00K$6.10M$9.10M$14.10M$14.90M$18.80M$30.50M$35.60M$50.40M$29.70M$47.80M$64.90M$40.20M$49.10M$40.60M$33.30M$16.40M$9.00M$17.80M
QoQ Change—>999%+516.2%+49.2%+54.9%+5.7%+26.2%+62.2%+16.7%+41.6%-41.1%+60.9%+35.8%-38.1%+22.1%-17.3%-18.0%-50.8%-45.1%+97.8%
YoY Change————>999%>999%+208.2%+235.2%+152.5%+238.3%+58.0%+56.7%+82.3%-20.2%+65.3%-15.1%-48.7%-59.2%-81.7%-56.2%
Range$47.00K – $64.90M
CAGR+249.0%
Avg YoY Growth>999%
Median YoY Growth+61.6%

Frequently Asked Questions

What is Vertex Pharmaceuticals's debt and equity securities, unrealized loss?
Vertex Pharmaceuticals (VRTX) reported debt and equity securities, unrealized loss of $17.80M in Q1 2026.
How has Vertex Pharmaceuticals's debt and equity securities, unrealized loss changed year-over-year?
Vertex Pharmaceuticals's debt and equity securities, unrealized loss decreased by 56.2% year-over-year, from $40.60M to $17.80M.
What is the long-term trend for Vertex Pharmaceuticals's debt and equity securities, unrealized loss?
Over 5 years (2020 to 2025), Vertex Pharmaceuticals's debt and equity securities, unrealized loss has grown at a 157.8% compound annual growth rate (CAGR), from $79.00K to $9.00M.